DOI QR코드

DOI QR Code

Distinctions Between Clinicopathological Factors and Prognosis of Alpha-fetoprotein Negative and Positive Hepatocelluar Carcinoma Patients

  • Xu, Jia (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Liu, Chang (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Zhou, Lei (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Tian, Feng (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Tai, Ming-Hui (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Wei, Ji-Chao (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Qu, Kai (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Meng, Fan-Di (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Zhang, Ling-Qiang (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Wang, Zhi-Xin (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Zhang, Jing-Yao (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Chang, Hu-Lin (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Liu, Si-Nan (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Xu, Xin-Shen (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Song, Yan-Zhou (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Liu, Jun (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University) ;
  • Zhang, Peng (Department of Hepatobiliary Surgery, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University)
  • Published : 2012.02.29

Abstract

Serum alpha-fetoprotein (AFP) is a significant marker for clinical diagnosis and prognosis evaluation in hepatocellular carcinoma (HCC) patients. However, some proportion of liver cancer patients are AFP-negative (AFP ${\leq}$20ng/ml). In order to study the differences between clinicopathological factors and prognosis of alpha-fetoprotein negative and positive patients, a total of 114 cases (41 AFP-negative and 73 AFP-positive) were selected for our research. By systematically statistical analysis, the results demonstrated that compared with AFP-negative patients, AFP-positive examples were more likely to feature cirrhosis nodules, non-complete neoplasm capsules, and a poor Edmondson-steiner grade. Furthermore, AFP-negative patients demonstrated a favorable long-term prognosis. By univariate analysis and multivariate analysis with Cox's proportional hazards model, multiple tumors were found to be independent risk factors for worse survival of AFP negative patients; however, less tumor-free margins, multiple tumors and Edmondson-steiner grades III/IV, proved to be independent risk factors leading to a poor prognosis of AFP positive cases. Finally, we can infer that high levels of AFP signify a highly malignant tumor and unfavorable prognosis.

Keywords

Clinicopathological factors;prognosis;alpha-fetoprotein status;hepatocellular carcinoma

References

  1. Alpert ME, Uriel J, de Nechaud B (1968). Alpha1 fetoglobulin in the diagnosis of human hepatoma. N Engl J Med, 278, 984-6. https://doi.org/10.1056/NEJM196805022781804
  2. Abelev G (1971). Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res, 14, 295-358. https://doi.org/10.1016/S0065-230X(08)60523-0
  3. Chang YC, Nagasue N, Abe S, et al (1992). Comparison between the clinicopathologic features of AFP-positive and AFPnegative gastric cancers. Am J Gastroenterol, 87, 321.
  4. Debruyne EN, Delanghe JR (2008). Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clinica Chimica Acta, 395, 19-26. https://doi.org/10.1016/j.cca.2008.05.010
  5. Fujiyama S, Tanaka M, Maeda S, et al (2002). Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology, 62, 57. https://doi.org/10.1159/000048277
  6. Farinati F, Marino D, De Giorgio M, et al (2006). Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol, 101, 524-32. https://doi.org/10.1111/j.1572-0241.2006.00443.x
  7. Gitlin D, Boesman M (1966). Serum alpha-fetoprotein, albumin, and gamma-G-globulin in the human conceptus. J Clinic Invest, 45, 1826. https://doi.org/10.1172/JCI105486
  8. Gitlin D, Perricelli A, Gitlin GM (1972). Synthesis of -fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res, 32, 979-82.
  9. Jemal A (2011). Global Cancer Statistics (vol 61, pg 69, 2011). Ca-Cancer J Clin, 61, 134.
  10. Lok ASF, Lai CL (1989). $\alpha$-fetoprotein monitoring in chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma. Hepatology, 9, 110-5. https://doi.org/10.1002/hep.1840090119
  11. Li MS, Ma QL, Chen Q, et al (2005). Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J Gastroenterol, 11, 2564-9. https://doi.org/10.3748/wjg.v11.i17.2564
  12. Maringhini A, Cottone M, Sciarrino E, et al (1988). Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci, 33, 47-51. https://doi.org/10.1007/BF01536630
  13. Nagao M, Nakajima Y, Kanehiro H, et al (2000). The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology, 32, 491-500. https://doi.org/10.1053/jhep.2000.16470
  14. Peng SY, Chen WJ, Lai PL, et al (2004). High $\alpha$-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age, p53 and $\beta$-catenin mutations. Int J Cancer, 112, 44-50. https://doi.org/10.1002/ijc.20279
  15. Ryder S (2003). Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut, 52, iii1.
  16. Velazquez RF, Rodriguez M, Navascues CA, et al (2003). Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology, 37, 520-7. https://doi.org/10.1053/jhep.2003.50093
  17. Wang XW, Xie H (1999). Significance of a-fetoprotein in the development of novel therapeutic agents. Drugs of the Future, 24, 55-66. https://doi.org/10.1358/dof.1999.024.01.858616
  18. Zhou L, Rui JA, Ye DX, et al (2008). Edmondson-Steiner grading increases the predictive efficiency of TNM staging for longterm survival of patients with hepatocellular carcinoma after curative resection. World J Surg, 32, 1748-56. https://doi.org/10.1007/s00268-008-9615-8

Cited by

  1. Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey vol.13, pp.6, 2012, https://doi.org/10.7314/APJCP.2012.13.6.2985
  2. Crosstalk between EGFR and p53 in Hepatocellular Carcinoma vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8069
  3. Retrospective Evaluation of Discrepancies between Radiological and Pathological Size of Hepatocellular Carcinoma Masses vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9487
  4. Multicenter Epidemiologic Study on Hepatocellular Carcinoma in Turkey vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2923
  5. Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3915
  6. Estimation of Leucine Aminopeptidase and 5-Nucleotidase Increases Alpha-Fetoprotein Sensitivity in Human Hepatocellular Carcinoma Cases vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.959
  7. Protein microarray with horseradish peroxidase chemiluminescence for quantification of serum α-fetoprotein vol.43, pp.5, 2015, https://doi.org/10.1177/0300060515583075
  8. Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease vol.89, pp.6, 2016, https://doi.org/10.1002/jmv.24720
  9. Histological Grading of Hepatocellular Carcinoma—A Systematic Review of Literature vol.4, pp.2296-858X, 2017, https://doi.org/10.3389/fmed.2017.00193